torvastatin metabolized by cytochrome P450 3A4
senting within 6 h of symptoms were included in the study. UAP was defined as AP with at least 1 of 3 features: occurring at rest and usually lasting >20 min, new onset within 1 month, and a crescendo pattern. Non-ST-elevation MI was defined as AP with elevated cardiac serum markers, such as creatine kinase isoenzyme-MB and/or troponin T or I. STelevation MI was defined as AP with ECG evidence of at least 2-mm ST elevation in 2 anterior lateral leads or at least 2-mm ST elevation in 2 inferior leads or a new left bundlebranch block with at least 1-mm concordant ST elevation and/or elevated cardiac serum markers. We excluded patients with Killip class IV MI, left main coronary lesion, prior history of interventional or surgical treatment for coronary artery disease (CAD), cerebrovascular disease, uncontrolled arrhythmia within 3 months, severe left ventricular dysfunction (ejection fraction <20%), serum creatinine >2.0 mg/dl, use of intravascular glycoprotein IIb/IIIa inhibitors, cilostazol and warfarin. Patients with previous use of clopidogrel and statins (atorvastatin, lovastatin, and simvastatin), which are metabolized in vivo predominantly by CYP3A4, were also excluded. The use of rifampin, phenytoin, antifungal agents, and macrolide antibiotics was not permitted during the study. The study was approved by the University Hospital Institute Review Board, and all participants gave written informed consent.
Diabetes mellitus was defined as known history, fasting plasma glucose concentration ≥126 mg/dl, or the use of hypoglycemic medications. Systemic hypertension was defined as systolic blood pressure ≥140 mmHg, diastolic pressure ≥90 mmHg, or the use of antihypertensive medication. Hyperlipidemia was defined as total cholesterol (TC) ≥200 mg/dl, low-density lipoprotein-cholesterol (LDL-C) ≥130 mg/dl, or treatment with a lipid-lowering agent. Smoker was defined as either current or a recent history of smoking within the past 1 year. Family history of premature CAD was defined as CAD in male first-degree relative aged <55 years or female first-degree relative <65 years. Body mass index (BMI) was calculated by dividing the square of the height in meters from the weight in kilograms.
Platelet Aggregation Analysis
Measurement of platelet aggregation was done by the turbimetric method using a Chronolog Lumi-Aggregometer (model 590-2DR; Chronolog Corporation, Havertown, PA, USA) equipped with AggroLink software. Measurement of platelet aggregation was done at baseline before clopidogrel and atorvastatin administration, then repeated at 4 h, 24 h, 5 days and 8 months later. Platelet-rich plasma (PRP) and platelet-poor plasma (PPP) were prepared by differential centrifugation (160 g for 10 min or 1,100 g for 15 min, respectively). PRP (0.5 ml) was incubated at 37°C in the aggregometer for 2 min followed by the addition of adenosine diphosphate (ADP) 5 and 20 μmol/L with continuous stirring at 1,300 rpm. Light transmission was adjusted to 0% with PRP and to 100% for PPP for each measurement. Platelet aggregation was recorded up to 5 min and expressed as the maximal % change of light transmission from baseline using PPP as a reference.
Angiographic Analysis and Percutaneous Coronary Intervention
Coronary angiograms were obtained at baseline, immediately after stenting, and at 8-month follow-up; 2 identical orthogonal views were obtained after intracoronary administration of nitrates and stored on digital CD-ROM. All angiographic and clinical data were sent to Korea University Anam Hospital core laboratory for analyses. End-diastolic frames were chosen for quantitative analysis, which was performed using a computer-based TCS system (Version 2.02; Medcon Inc, Tel-Aviv, Israel) by an operator who was unaware of the patient's information. The reference diameter, minimal luminal diameter, percentage of stenosis, and lesion length were calculated as the average value of the 2 orthogonal views. The same views and calibration were used at follow-up angiography. The average diameters of normal segments proximal and distal to the treated lesion were used as the reference. Restenosis was defined as >50% of the luminal diameter. Mehran et al's classification was used for description of the in-stent restenosis pattern. 10 Balloon angioplasty and stent implantation were performed according to standard clinical practice. Either the femoral or radial approach was used, and all patients started with 200 mg of aspirin combined with 300 mg of clopidogrel before the procedure. Aspirin was given indefinitely, and 75 mg of clopidogrel was given once daily for 8 months. At the beginning of the intervention, a heparin bolus of 100 units/kg was administered after sheath insertion, and supplemental doses were then given to maintain an activated clotting time >300 s. Various guiding catheters, 6F-, 7F-, or 8F-large lumen, and 0.014-inch guidewires were used. All patients underwent balloon predilatation before stenting, and the size of the balloon was determined by the target vessel size. SES (Cypher ® , Cordis) were used in all participating patients. High-pressure balloon inflation was used in order to avoid stent underexpansion. Intravascular ultrasound (IVUS) was used in some cases if necessary. Procedural success was defined as residual stenosis <15% in the absence of closure during the first 48 h after the procedure.
Follow-up
A complete clinical workup was scheduled at 1, 4 and 8 months following the procedure, and the 8-months angiographic follow-up was not mandatory. If clinically indicated, follow-up angiography was performed earlier. Major adverse cardiovascular events, which included cardiac death, MI and the need for repeated target vessel revascularization within 8 months, were noted. The primary endpoint of the study was determining the differences in serial % platelet aggregation during the 8-month follow-up. The secondary endpoints were to determine the differences in the level of inflammatory markers, such as interleukin (IL)-6, tumor necrosis factor (TNF)-α, high-sensitivity C-reactive protein (hs-CRP), soluble intercellular adhesion molecule-1 (sICAM-1), soluble vascular cell adhesion molecule-1 (sVCAM-1), adiponectin and to find out the differences in clinical events such as death, MI, the need for repeated target lesion revascularization, target vessel revascularization, and stent thrombosis during the 8-month follow-up.
Laboratory Analysis
Inflammatory markers were measured in both groups at the beginning of the study and at 8 months. Venous blood samples were drawn from each patient after 8-h or overnight fasting. Blood samples were centrifuged to obtain plasma, which was stored at -80°C. TNF-α was measured by a sandwich enzyme-linked immunosorbent assay (ELISA) with a minimum detectable level of 0.5 pg/ml (ALPCO Diagnostics, Salem, NH, USA). Undetectable TNF-α values were recorded as 0.4 pg/ml. High-sensitivity IL-6 was also measured by a sandwich ELISA with a minimum detectable level of 0.16 pg/ml (ALPCO Diagnostics). The hs-CRP concentrations were quantified using a latex nephelometer II (Dade Behring Inc, Newark, DE, USA). The sICAM-1 and sVCAM-1 concentrations were measured using a commercially available ELISA, according to the manufacturer's instructions (R&D Systems, Minneapolis, MN, USA). The plasma adiponectin concentration was assessed by radioimmunoassay (Linco Research, Inc, St Charles, MO, USA). The sensitivity of this assay was 0.78 ng/ml. The intra-and interassay coefficients of variation were 9.3% and 15.3%, respectively. TC, triglycerides (TG), high-density lipoprotein-cholesterol (HDL-C), and LDL-C concentrations were determined by enzymatic methods using standard biochemical procedures on a B.M. Hitachi automated clinical chemistry analyzer (Hitachi, Tokyo, Japan).
Statistical Analysis
Data are expressed as mean ± SD for continuous variables, and data for the categorical variables are expressed as the number and % of patients. Fisher's exact test or a chi-square test was used for categorical variables. The results between 2 groups were compared by an unpaired Student's t-test, and the comparisons between before and after treatment were analyzed by a paired t-test. Because there has not been a previous trial that has examined the effect of atorvastatin on clopidogrel resistance in patients with ACS, the Cohen method was used to estimate the sample size ( α=0.05, β= 0.1, 2-tailed), resulting in 51 patients in each group. To account for 20% dropout, at least 64 patients were needed in each group. Angiographic analyses were performed accord- ing to the number of patients available for each analysis. All analyses were performed according to the intention-totreat principle. Geometric mean and SD values are given for variables that did not show normal distribution. A P value less than 0.05 was considered significant. SPSS software (version 10.0; Chicago, IL, USA) was used for analyses.
Results

Study Patients
Baseline clinical characteristics of the ATOR10 Group (n=65) and the ATOR40 Group (n=65) were similar ( Table 1 ). The mean ages were similar (61.4±9.3 and 60.7± 10.5 years), as were the mean BMIs (23.8±2.1 and 24.8± 4.6 kg/m 2 ), between the 2 groups. The rates of diabetes, hypertension, hyperlipidemia and current smoking at baseline were similar between the 2 groups. The incidence of ST-elevation MI was not significantly different between the 2 groups [11 patients (16.9%) in the ATOR10 Group and 8 patients (12.3%) in the ATOR40 Group, P=0.456]. The use of the various active medications at baseline was similar between the 2 groups ( Table 2) .
Baseline Procedural Characteristics
More than 45% of patients in each group had the left anterior descending artery as a main target vessel. The results of quantitative coronary angiography (CAG) are listed in Table 3 . Lesions were characterized according to the modified American College of Cardiology/American Heart Association classification. Complex lesion such as type B2 or C affected more than 50% of patients in both groups [37 patients (56.9%) in the ATOR10 Group and 34 patients (52.3%) in the ATOR40 Group]. Baseline reference diameter, minimal luminal diameter, percentage of stenosis, and mean lesion length were similar in both groups with no significant differences.
Mean Percentage Changes in Inhibition of Platelet Aggregation and 8-Month Angiographic and Clinical Follow-up
Mean % change in inhibition of platelet aggregation after stenting demonstrated no significant differences between the 2 groups (Figure 2) . The 8-month angiographic follow-up rates were similar between the 2 groups ( Table 4) , and there were no significant differences in late lumen loss or binary restenosis rate at that time. One case of subacute stent throm- (Figure 3) .
Comparisons of Biochemical Parameters at Baseline and Follow-up CAG
Inflammatory markers such as IL-6, TNF-α, hsCRP, and sICAM-1 had decreased significantly at 8-month follow-up compared with baseline in both groups; however, the change from baseline showed no significant differences between groups ( Table 5 ). The adiponectin concentration increased significantly compared with baseline in both groups; however, the change from baseline showed no significant differ- 
Discussion
Clopidogrel is a thienopyridine prodrug that needs to be metabolized in several steps by cytochrome P-450 isoenzymes in order to biotransform to the active metabolite, which binds irreversibly to the platelet ADP receptor P2Y12. 11 Clopidogrel reduces platelet activation and aggregation, thereby playing an important role in modifying the pathophysiology of ACS. [12] [13] [14] Clopidogrel actually reduced the incidence of recurrent ischemic events in patients with ACS and in patients after bare-metal stenting. 15, 16 Because clopidogrel decreases the incidence of stent thrombosis, the current ACC/AHA guideline recommends its use for at least 1 year in patients with ACS after DES implantation. 17, 18 Clopidogrel is currently 1 of the most widely prescribed antiplatelet drugs in the era of DES.
Atorvastatin is a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor (statin) commonly used to treat hypercholesterolemia. In Korea it is frequently co-administered with clopidogrel in patients with ACS after DES implantation. Because clopidogrel and atorvastatin are both metabolized by cytochrome P-450 isoenzymes in the liver, 19 theoretically the antiplatelet potency of clopidogrel could be diminished when co-administered with atorvastatin, which could be life-threatening after DES implantation. Possible interactions between clopidogrel and atorvastatin would be especially critical in ACS patients during the early period after stent implantation. Because there has not been a clear answer regarding the antiplatelet activity of clopidogrel when coadministerd with atorvastatin 10 mg or 40 mg in patients with ACS, we conducted this prospective, randomized, single-blind, investigator-initiated study to investigate the effect of atorvastatin 10 mg vs 40 mg in clopidogrel resistance and on clinical events after SES implantation in Korean patients with ACS. We looked closely at the early clopidogrel and atorvastatin interactions, 4 and 24 h after the initial loading dose of 300 mg of clopidogrel with atorvastatin. Moreover, possible late clopidogrel and atorvastatin interactions were monitored 5 days and 8 months after the surgical intervention.
Lau et al demonstrated a dose-dependent attenuation of the antiplatelet efficacy of clopidogrel 24 h after atorvastatin administration, 1 and Neubauer et al has reported decreased antiplatelet efficacy of clopidogrel by atorvastatin during the loading period. 20 However, others have suggested that atorvastatin does not influence the antiplatelet effect of clopidogrel. 3, 5, 21 Many clinicians were confused by these controversial results and questioned the safety of clopidogrel and atorvastatin co-administration in "real world" clinical practice. Large clinical trials have answered this question about safety; for example, the Clopidogrel for Reduction of Events During Observation (CREDO) trial demonstrated that there was no adverse effect on the 1-year clinical outcomes with clopidogrel and lipophilic statin co-administration. 4 No evidence of a clopidogrel and lipophilic statin interaction was shown in the CHARISMA trial or in the prospective Maximal Individual TheRapy of Acute myocardial infarction PLUS (MITRA PLUS) registry. 6, 22 Ours is the first study, to the best of our knowledge, that has investigated the antiplatelet effects of clopidogrel with different doses of co-administered atorvastatin both during the early period after SES implantation and at 8 months later in ACS patients. Our results demonstrated that atorvastatin did not have an adverse interaction with clopidogrel with regard to platelet function and did not affect the clinical outcome, at least up to 8 months, in ACS patients. One possible explanations for the lack of a clopidogrel-atorvastatin interaction Table 4 .
is the various cytochrome P-450 isoenzymes in the liver. Clopidogrel is mainly metabolized into its active metabolite via cytochrome P-450 3A4; however, upregulation of cytochrome P-450 2B6, 2C19 could compensate for decreased activity of cytochrome P-450 3A4 during clopidogrel and atorvastatin co-administation, even in the early stage. 5, 23 Although the lipid profiles were more favorable in the ATOR40 Group regarding the LDL-C and TC concentrations, no significant differences were found in reducing late lumen loss and inflammatory markers, such as IL-6, TNF-α, sICAM-1, sVCAM-1 and hs-CRP, compared with the ATOR10 Group. This might be because other medications, such as angiotensin-converting enzyme inhibitors and angiotensin-receptor blockers, were administered during the study. Major adverse cardiovascular events (death, MI, target vessel revascularization) were also similar between the 2 groups, partly because of the relatively small study participants and the administration of aspirin and clopidogrel in addition to other anti-angina medications during the study. We coincidentally found 1 case of subacute stent thrombosis in the ATOR40 Group during the second-stage coronary intervention. The thrombus was relatively small, and the patient did not complain of any ischemic symptoms. Coronary angiography was repeated 3 days after continuous heparin injection and no residual thrombus was found at that time or on the 8-month follow-up coronary angiogram. No correlation between stent thrombosis and atorvastatin 40 mg administration was found in this study (0% in the ATOR10 Group and 1.6% in the ATOR40 Group, P=0.952), and so other possibilities, such as polymorphism of P2Y12 or cytochrome families, should be investigated.
Study Limitations
We could not exclude clopidogrel nonresponders from this study; however, the incidence of clopidogrel nonresponders is known to be <10%, 24 and patients were randomly assigned to reduce this bias. Polymorphism of CYP2C19 could have affected clopidogrel resistance in this study, 25 and patients were randomly assigned to reduce that effect. Racial differences in atorvastatin and clopidogrel interactions would not be an explanation in this study, because all enrolled patients were Koreans. Because the patients were randomly assigned, the effects of aspirin resistance on clinical events could be minimized. Prospective, randomized studies with more participants are warranted to determine differences in clinical events with different doses of atorvastatin and clopidogrel co-administration.
In summary, atorvastatin 10 mg or 40 mg co-administered with clopidogrel for 8 months did not affect the antiplatelet potency of clopidogrel, and no significant differences in clinical events were noted between the 2 groups. Atorvastatin 10 mg or 40 mg co-administered with clopidogrel for 8 months is safe and effective in ACS patients.
